QNRX
Quoin Pharmaceuticals, Ltd.11.72
+1.57+15.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.83MP/E (TTM)
-Basic EPS (TTM)
-29.17Dividend Yield
0%Recent Filings
8-K
FDA Fast Track for QRX003
Quoin Pharmaceuticals announced on March 11, 2026, that the FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder lacking approved treatments. This speeds development via frequent FDA interactions and potential rolling review. QRX003 advances in two late-stage trials. Prior Orphan and Pediatric Rare Disease nods build momentum.
8-K
Quoin seeks SFDA breakthrough status
Quoin filed for Breakthrough Medicine Designation with Saudi Arabia's SFDA for QRX003, its late-stage topical for Netherton Syndrome, on January 20, 2026. If granted, accelerated review could enable sales there by 2H 2026 via Genpharm partnership. Enrollment wraps H1 2026. Trials carry approval risks.
8-K
Approves stock option forms
Quoin Pharmaceuticals' Compensation Committee approved forms of incentive and non-qualified stock option award agreements on November 14, 2025, under its 2025 Equity Incentive Plan for directors and executives. These enable flexible vesting and exercise methods like cashless mechanisms. Termination rules vary: vested options exercisable up to 1 year post-death/disability, 3 months otherwise. No grants issued yet.
8-K
Rapamycin loadings achieved
Quoin Pharmaceuticals hit target rapamycin loadings of 4% w/w in its proprietary topical lotion and 5% w/w in a dermal patch on November 11, 2025. The company will manufacture clinical trial batches this quarter, targeting microcystic lymphatic malformations and venous malformations—indications lacking FDA-approved treatments—in 1H 2026. Progress bolsters its rare disease pipeline. Clinical timelines carry delay risks.
10-Q
Q3 FY2025 results
Quoin Pharmaceuticals posted a Q3 net loss of $3.9M, up 68% y/y from $2.3M, driven by R&D expenses doubling to $2.3M on external clinical costs for QRX003, while G&A rose 20% to $1.7M amid severance. YTD net loss widened to $11.5M from $6.7M, with operating cash burn at $8.5M; capex not disclosed so FCF not disclosed in the 10-Q. Cash fell to $1.8M and investments to $3.6M, offset by $7.6M due officers and October's $16.6M private placement plus $3.3M warrant exercises. Losses match operating losses. Cash runway extended.
BLRX
BioLineRx Ltd.
3.01-0.17
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
CNTA
Centessa Pharmaceuticals plc
25.72-0.43
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
QNCX
Quince Therapeutics, Inc.
3.70-0.07
QTTB
Q32 Bio Inc.
2.88-0.17
QURE
uniQure N.V.
21.89+1.46
RPRX
Royalty Pharma plc
38.38-0.15
XRTX
XORTX Therapeutics Inc.
0.59-0.01